

## LUNG CLINICAL AND TREATMENT DATA COLLECTION FORM

*To be completed by 3 months post-radiotherapy follow-up*

Study Number

RQ□□□□□-□

Patient Initials

□□□□

Date of Birth (dd/mm/yyyy)

□□/□□/□□□□

Date Completed (dd/mm/yyyy)

□□/□□/□□□□

Name + Signature of Person completing the CRF

### Tumour Histology

Date of pathological diagnosis  
(dd/mm/yyyy)

□□/□□/□□□□

Side of Primary

☐

1=RUL  
2=RML  
3=RLL  
4=R. Lung  
5=LUL  
6=Lingular  
7=LLL  
8=L.Lung

Histology  
(pre RT)

☐

1=Squamous  
2=Adenocarcinoma  
3=Large cell  
4=Mixed  
5=Undifferentiated  
6=Not specified  
7=Other, specify \_\_\_\_\_

Clinical T Stage  
(pre RT):

☐

0

☐

1a

☐

1b

☐

2a

☐

2b

☐

3

☐

4

Clinical N Stage  
(pre RT):

☐

0

☐

1

☐

2

☐

3

Stage based on

☐

1=CT  
2=PET CT  
3=MRI  
4=Other, specify \_\_\_\_\_

Stage at  
diagnosis

☐

1=I  
2=II  
3=IIIa  
4=IIIb  
9=Not known

### Surgical and Systemic Therapy

Surgical  
intervention

☐

0=No  
1=Yes, pneumonectomy  
2=Yes, lobectomy (# of removed lobes \_\_\_\_\_)  
3=Yes, wedge resection/segmentectomy  
9=Not known

If yes, Date  
(dd/mm/yyyy)

□□/□□/□□□□

Chemotherapy

☐

0=No  
1=Yes  
9=Not known

If yes, Start Date  
(dd/mm/yyyy)

□□/□□/□□□□

Date of last dose  
(dd/mm/yyyy)

□□/□□/□□□□

Schedule

☐

0=Sequential  
1=Concurrent  
2=Induction + concurrent  
3=Concurrent + consolidation  
4=Consolidation  
9=Not known

Cycles of induction chemotherapy

☐

Cycles of concurrent chemotherapy

☐

Cycles of consolidation chemotherapy

☐

Chemotherapy used

**Radiotherapy**

Date radiotherapy started (dd/mm/yyyy)

□□/□□/□□□□

Date radiotherapy finished (dd/mm/yyyy)

□□/□□/□□□□

Radiotherapy interrupted for more than 3 days

☐0=No  
1=Yes  
9=Not known

If yes, reason

Radiotherapy technique

☐1=3D CRT  
2=ARC therapy (eg VMAT, RapidARC)  
3=IMRT  
4=Tomotherapy  
5=Stereotactic body radiation therapy/stereotactic ablative radiotherapy

Treatment planning system algorithm

☐1=Pencil beam  
2=Collapsed cone  
3=Monte Carlo  
4=Accuros or similar  
5=Other

Dose per fraction (Gy)

□□.□□

Fractions per week

□□

Total Dose (Gy)

□□.□□

Total number of Fractions

□□GTV (tumour & nodes if applicable (cm<sup>3</sup>))□□.□□

Mean Lung\* Dose (Lung - GTV) (Gy)

□□.□□PTV (tumour & nodes if applicable (cm<sup>3</sup>))□□.□□

V5 (%) Lung\* - PTV

□□.□□CTV (tumour & nodes if applicable (cm<sup>3</sup>))□□.□□

V20 (%) Lung\* - PTV

□□.□□

V35 (%) Oesophagus

□□.□□

V5 (%) Heart

□□.□□

V50 (%) Oesophagus

□□.□□

V30 (%) Heart

□□.□□

V60 (%) Oesophagus

□□.□□

V40 (%) Heart

□□.□□

Max dose to 1cc Oesophagus (Gy)

□□.□□

V50 (%) Heart

□□.□□

Mean Oesophageal dose (Gy)

□□.□□

Max dose to 1cc of Heart (Gy)

□□.□□Definition for heart delineation:

The heart should be outlined along with the pericardial sac. The pericardial sac surrounds the heart and extends superiorly to encompass the main pulmonary artery, the ascending aorta and the superior vena cava. Outlining should extend superiorly to the inferior limit of the aortic arch (the aortopulmonary window) and the superior limit of the trunk of the pulmonary artery if it can be identified on the radiotherapy planning CT scan.

Mean Heart dose (Gy)

□□.□□

Heart delineation

☐1=As defined  
2=Left ventricle only  
3=Others

\*Lung = both lungs together